Literature DB >> 20630856

Natural immunization against malaria: causal prophylaxis with antibiotics.

Johannes Friesen1, Olivier Silvie, Elyzana Dewi Putrianti, Julius C R Hafalla, Kai Matuschewski, Steffen Borrmann.   

Abstract

Malaria remains the most prevalent vector-borne infectious disease and has the highest rates of fatality. Current antimalarial drug strategies cure malaria or prevent infections but lack a sustained public health impact because they fail to expedite the acquisition of protective immunity. We show that antibiotic administration during transmission of the parasite Plasmodium berghei results in swift acquisition of long-lived, life cycle-specific protection against reinfection with live sporozoites in mice. Antibiotic treatment specifically inhibits the biogenesis and inheritance of the apicoplast in Plasmodium liver stages, resulting in continued liver-stage maturation but subsequent failure to establish blood-stage infection. Exponential expansion of these attenuated liver-stage merozoites from a single sporozoite induces potent immune protection against malaria. If confirmed in residents of malaria-endemic areas, periodic prophylaxis with safe and affordable antibiotics may offer a powerful shortcut toward a needle-free surrogate malaria immunization strategy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630856     DOI: 10.1126/scitranslmed.3001058

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  66 in total

Review 1.  The apicoplast.

Authors:  Geoffrey Ian McFadden
Journal:  Protoplasma       Date:  2010-12-17       Impact factor: 3.356

Review 2.  Looking under the skin: the first steps in malarial infection and immunity.

Authors:  Robert Ménard; Joana Tavares; Ian Cockburn; Miles Markus; Fidel Zavala; Rogerio Amino
Journal:  Nat Rev Microbiol       Date:  2013-10       Impact factor: 60.633

3.  Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection.

Authors:  Xiaohong Peng; Gladys J Keitany; Marissa Vignali; Lin Chen; Claire Gibson; Kimberly Choi; Fusheng Huang; Ruobing Wang
Journal:  J Immunol       Date:  2014-06-23       Impact factor: 5.422

4.  Identifying apicoplast-targeting antimalarials using high-throughput compatible approaches.

Authors:  Eric H Ekland; Jessica Schneider; David A Fidock
Journal:  FASEB J       Date:  2011-07-11       Impact factor: 5.191

5.  CD8 T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii.

Authors:  Katherine L Doll; Noah S Butler; John T Harty
Journal:  Vaccine       Date:  2013-12-07       Impact factor: 3.641

Review 6.  Immune mechanisms in malaria: new insights in vaccine development.

Authors:  Eleanor M Riley; V Ann Stewart
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

Review 7.  Live attenuated pre-erythrocytic malaria vaccines.

Authors:  Gladys J Keitany; Marissa Vignali; Ruobing Wang
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  A key role for lipoic acid synthesis during Plasmodium liver stage development.

Authors:  Brie Falkard; T R Santha Kumar; Leonie-Sophie Hecht; Krista A Matthews; Philipp P Henrich; Sonia Gulati; Rebecca E Lewis; Micah J Manary; Elizabeth A Winzeler; Photini Sinnis; Sean T Prigge; Volker Heussler; Christina Deschermeier; David Fidock
Journal:  Cell Microbiol       Date:  2013-04-05       Impact factor: 3.715

9.  Evaluation of the Combination of Azithromycin and Naphthoquine in Animal Malaria Models.

Authors:  Zhu-Chun Bei; Guo-Fu Li; Jing-Hua Zhao; Min Zhang; Xiao-Guang Ji; Jing-Yan Wang
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 10.  Murine infection models for vaccine development: the malaria example.

Authors:  Kai Matuschewski
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.